SAN DIEGO--( BUSINESS WIRE)--Ignyta, Inc., the personalized medicine company dedicated to improving the diagnosis and treatment of patients with rheumatoid arthritis, lupus and other autoimmune diseases, announced today the appointment of Professor Tom Huizinga, Chairman of the Department of Rheumatology at Leiden University Medical Center (LUMC), to its Scientific Advisory Board.
is one of the most published and cited authors in the field of rheumatology, particularly on the topic of detection of early stage rheumatoid arthritis where Ignyta
has a strong focus."
Tom Huizinga is a Professor and Chairman of the Department of Rheumatology at Leiden University Medical Center (LUMC) in Leiden, Netherlands.
Professor Huizinga was a member of the Annual Meeting Planning Committee of the American College of Rheumatology (ACR) from 2000 to 2003, and the Annual Meeting Planning Committee of the European League Against Rheumatism (EULAR) from 2004 to 2007.
In 2006, he was appointed as a member of the Henry Kunkel Society, New York.
In 2005/2006, he served as a member of the "Verkenningscommissie Multifactoriele Aandoeningen in het Genomics Tijdperk " of the Royal Dutch Academy of Sciences.
has won various prizes throughout his
academic career and has published over 500 peer-reviewed papers in the national and international literature.
He is member of the editorial boards of Plos Medicine, Annals of Rheumatic Diseases , Arthritis and Rheumatism, Current Rheumatology Reviews, Genes and Immunity , International Journal of Advances in Rheu matology, Joint Bone Spine, Revue du Rheumatism International Edition , Current Rheumatology Reviews, Clinical and Experimental Rheumatology.
Professor Huizinga graduated from the University of Amsterdam Medical School, studied at Dartmouth Medical School, and returned to the Netherlands to train in internal medicine/rheumatology.